Kok Tjie, Nyotohadi Denny
Faculty of Biotechnology, University of Surabaya, Surabaya, 60293, Indonesia.
Heliyon. 2023 Nov 24;10(1):e22837. doi: 10.1016/j.heliyon.2023.e22837. eCollection 2024 Jan 15.
The COVID-19 caused by the SARS-CoV-2 has become a great threat to humans. However, there is no recommendation for an effective and safe drug to treat the disease. The strategy developed in this study is to utilize biosurfactant potential activity of spp. and probiotics to prevent the virus from entering human body. The outer membrane of the virus is comprising of phospholipid compounds. Biosurfactants, are known to have detergent-like properties (able to dissolve lipids) that are safe for use. Thus, the biosurfactant potential activity of the multistrain probiotics extract is expected to be able to disrupt the phospholipid membrane, resulting in the inactivity of the virus to infect human body. The biosurfactant potential activity of the probiotics extract was evaluated using oil spreading, drop collapse, and emulsification methods. The virus infectivity was evaluated on the SARS-CoV-2 of delta variant as a virus model. The results indicated that the probiotics extract has biosurfactant potential activity, able to inhibit virus growth up to 99.9 % within 48 h in the prevention platform, and up to 99.6 % within 48 h in the treatment platform. Therefore, the multistrain probiotics extract was identified to have potential as a promising antiviral agent.
由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的2019冠状病毒病已对人类构成巨大威胁。然而,目前尚无关于治疗该疾病的有效且安全药物的推荐。本研究制定的策略是利用 spp. 和益生菌的生物表面活性剂潜在活性来防止病毒进入人体。病毒的外膜由磷脂化合物组成。已知生物表面活性剂具有类似洗涤剂的特性(能够溶解脂质),且使用安全。因此,预计多菌株益生菌提取物的生物表面活性剂潜在活性能够破坏磷脂膜,从而使病毒失去感染人体的活性。使用油扩散、液滴塌陷和乳化方法评估了益生菌提取物的生物表面活性剂潜在活性。以德尔塔变异株的SARS-CoV-2作为病毒模型评估病毒感染性。结果表明,益生菌提取物具有生物表面活性剂潜在活性,在预防平台上能够在48小时内将病毒生长抑制高达99.9%,在治疗平台上能够在48小时内将病毒生长抑制高达99.6%。因此,多菌株益生菌提取物被确定具有作为一种有前景的抗病毒药物的潜力。